Effect of Eye Movement Training on Sleep Quality of Patients with Advanced Lung Cancer Based on Pittsburgh Sleep Quality Index

Objective. To explore the effect of eye movement training on sleep quality of patients with advanced lung cancer based on the Pittsburgh Sleep Quality Index (PSQI). Methods. 120 advanced lung cancer patients admitted to our hospital from January 2019 to January 2020 were selected as the research object and divided into group A (PSQI scores ≥ 10 points, n = 60) and group B (PSQI < 10 points, n = 60). Routine nursing was performed to both groups, and patients in group A received the eye movement training additionally, so as to compare their PSQI scores, negative emotion scores, adverse reaction rate (ARR), Cancer Coping Modes Questionnaire (CCMQ) scores, and pain scores. Results. After training, group A obtained significantly better sleep quality ( P < 0.05 ), lower negative emotion scores ( P < 0.001 ), lower ARR ( P < 0.05 ), better CCMQ scores ( P < 0.05 ), and lower pain scores ( P < 0.001 ) than group B. Conclusion. Eye movement training should be promoted in practice because it can reduce negative emotions, alleviate pain sensation, improve sleep quality and body condition, and lower the ARR for advanced lung cancer patients.

Download Full-text

Auricular acupressure for cancer-related fatigue during lung cancer chemotherapy: a randomised trial

BMJ Supportive & Palliative Care ◽

10.1136/bmjspcare-2019-001937 ◽

2019 ◽

pp. bmjspcare-2019-001937 ◽

Cited By ~ 1

Author(s):

Lu Lin ◽

Yan Zhang ◽

Hong Ying Qian ◽

Jia Li Xu ◽

Cong Yan Xie ◽

...

Keyword(s):

Lung Cancer ◽

Sleep Quality ◽

Cancer Patients ◽

Magnetic Beads ◽

Physical Fatigue ◽

Lung Cancer Patients ◽

Cancer Related Fatigue ◽

Auricular Acupressure ◽

Group A ◽

Group B

PurposeTo evaluate the effect of auricular acupressure (AA) on cancer-related fatigue (CRF), sleep disturbance and anxiety in lung cancer patients undergoing chemotherapy.Materials and methodsPatients were recruited from the respiratory department of a general hospital and were randomised into three groups. A 9-week course of AA using Semen Vaccariae (SV) (Group A)/AA using magnetic beads (Group B)/routine care (Group C) was implemented. CRF scores were used as the primary outcome while the sleep and anxiety scores were the secondary outcomes. Analysis of variance and least significant difference t-test were used to determine the intergroup differences and paired-sample t-test was used for the intragroup comparison.Results100 lung cancer patients undergoing chemotherapy were included. Compared with Group C, AA could significantly alleviate CRF (F:24.63, p<0.01), especially for physical and affective fatigue and Group A was more effective for managing physical fatigue than Group B in per-protocol (PP) (−1.75 (−2.69 to –0.82), p<0.01)/Intention to Treat analysis (ITT) (−1.41 (−2.39 to –0.41), p=0.01) analysis. However, AA had no effect on cognitive fatigue. Compared with Group C, only Group A produced significant improvements in sleep quality in PP analysis (−1.17 (−2.23 to –0.10), p=0.03) while it yielded negative results in ITT analysis (−0.82 (−1.74 to 0.10), p=0.08). Compared with Group C, AA could significantly reduce anxiety in PP analysis (F:9.35, p<0.01) while there was no statistical difference between Group B and Group C (−0.95 (−2.81 to 0.90), p=0.31), Group A and Group B (−1.26 (−3.12 to 0.59), p=0.18) in ITT analysis.ConclusionAA can alleviate CRF of lung cancer patients undergoing chemotherapy, especially for physical and affective fatigue. AA using SV is more effective for physical fatigue while AA using magnetic beads works better for anxiety. However, AA cannot improve the sleep quality.Trial registration numberISRCTNregistry (ISRCTN16408424).

Download Full-text

Observation of clinical efficacy and survival of lung cancer patients with UMIPIC combined with low-dose chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e21605 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e21605-e21605

Author(s):

Jianbin Feng ◽

Peng Jing ◽

Feng Gao ◽

Jian Liu ◽

Wei Han ◽

...

Keyword(s):

Lung Cancer ◽

Survival Time ◽

Clinical Efficacy ◽

Adverse Reactions ◽

Low Dose ◽

Survival Rates ◽

Lung Cancer Patients ◽

Group A ◽

Group B ◽

Low Dose Chemotherapy

e21605 Background: To observe the clinical efficacy and survival of UMIPIC combined with low-dose chemotherapy in patients with lung cancer. Methods: 840 patients with lung cancer underwent UMIPIC treatment from January 2011 to December 2015 were selected as the study subjects, 341 cases combined with low-dose chemotherapy in group A and 499 cases not combined with chemotherapy in group B. All patients were diagnosed with lung cancer and signed a consent form for treatment. The patients were treated according to the UMIPIC treatment guidelines. This study was mainly to observe the adverse reactions, clinical efficacy, survival time and survival rate of lung cancer patients after receiving UMIPIC combined with or without low dose chemotherapy. Results: The common adverse reactions in group A were fever 38.12%, followed by pain 9.38%, hemoglobin 7.94%, white blood cells 5.01%, nausea 2.35%, liver function damage 1.19%, vomiting 1.17%, and kidney function damage 0.30%; Common adverse reactions in group B were fever 38.68%, followed by pain 13.23%, hemoglobin reduction 12.87%, white blood cell reduction 5.29%, nausea 2.00%, vomiting 2.00%, liver function damage 1.92%. The hemoglobin reduction in group A was significantly lower than that in group B (P < 0.05), and there was no difference in the other adverse reactions (P > 0.05). Clinical efficacy of the two groups revealed that the benefit rate of group A was 95.45% higher than that of group B 93.47% (P > 0.05). After follow-up, it was found that the average survival time and median survival time of patients in group A were 20.744 and 13.270 months, respectively, which were significantly higher than those of group B at 19.514 and 10.070 months (P < 0.05). The survival rates of the two groups of patients, The 1-year, 2-year, and 5-year survival rates of group A patients are 52.48%, 23.60%, and 16.95%, and the 1-year, 2-year, and 5-year survival rates of group B patients are 42.96% and 17.07 % And 10.26%, the one-year survival rate of group A was significantly higher than that of group B (P < 0.05). Conclusions: UMIPIC combined with low-dose chemotherapy has a good clinical effect in treating lung cancer without increasing the incidence of adverse reactions, and a significant effect on extending survival time and improving survival rate of lung cancer patients.

Download Full-text

Radio-frequency thermal ablation of lung cancer under epidural anaesthesia: comparison of the effectiveness of blocks between higher and mid-thoracic level

Journal of the Bangladesh Society of Anaesthesiologists ◽

10.3329/jbsa.v17i1.4050 ◽

2009 ◽

pp. 36-38

Author(s):

MR Khandoker ◽

H Razwanul ◽

H Rashadul ◽

AM Sarwar ◽

UH Shahera Khatun

Keyword(s):

Lung Cancer ◽

Thermal Ablation ◽

Heat Rate ◽

Epidural Block ◽

Epidural Needle ◽

Epidural Group ◽

Lung Cancer Patients ◽

Thoracic Epidural ◽

Group A ◽

Group B

Purpose of the investigation is to evaluate the effectiveness of high thoracic epidural block in comparison to mid-thoracic epidural during Radiofrequency ablation for lung cancer. 60 patients (38 male) were selected for epidural segmental block who were proposed for radiofrequency thermal ablation for lung cancer. Patients were randomly divided in 2 groups: Group-A, higher thoracic epidural group & Group-B, mid-thoracic epidural group. Under all aseptic preparation 18 G Epidural catheter was inserted through 18 G epidural needle and 4-6 ml of 0.5% bupivacaine was used during anaesthesia. Extend of block was demarcated by pain prick. RFT probe was allowed to insert 30 minutes after anaesthesia. The heat rate, blood pressure, respiration, Sp02 and temperature were monitored continuously during the procedure. Excellent block was found in 21 cases of Group-A and 15 cases of Group-B. Anaesthesia was inadequate in two cases of Group-A, and in 5 cases of Group-B, So, Higher thoracic epidural technique is better than mid thoracic epidural.DOI: http://dx.doi.org/10.3329/jbsa.v17i1.4050 Journal of BSA, Vol. 17, No. 1 & 2, 2004 p.36-38

Download Full-text

The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis

Iranian Journal of Public Health ◽

10.18502/ijph.v48i7.2949 ◽

2020 ◽

Author(s):

Youhua JIANG ◽

Kewei NI ◽

Meiyu FANG ◽

Junling LIU

Keyword(s):

Lung Cancer ◽

Pulmonary Tuberculosis ◽

Cancer Patients ◽

Serum Levels ◽

Incidence Rates ◽

Lung Cancer Patients ◽

Group A ◽

Male Patients ◽

Hs Crp ◽

Group B

Background: This study intended to investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) on the incidence of lung cancer in male patients with pulmonary tuberculosis. Methods: A total of 1091 male patients with pulmonary tuberculosis in Zhejiang Cancer Hospital, Hangzhou, China from Jan 2009 to Jan 2012 were selected as the research objects. All patients were followed up from the beginning of hospitalization. According to serum hs-CRP level, patients were divided into two groups: group A (hs-CRP < 1 mg/L) and group B (hs-CRP > 3 mg/L). The relationship between baseline hs-CRP and the risk of lung cancer in patients with pulmonary tuberculosis was analyzed by multivariate Cox proportional risk regression model, and the serum levels of hs-CRP between lung cancer patients in all groups and other non-lung cancer patients were compared. Results: There were differences in age, drinking, smoking, diabetes history, body mass index (BMI), thyroglobulin (TG), history of hypertension and hyperglycemia among the three groups (P=0.036, 0.018, 0.040, 0.029, 0.006, 0.034, 0.020, 0.010). The serum levels of hs-CRP in patients with squamous carcinoma, adenocarcinoma and small cell carcinoma were significantly higher than those in non-lung cancer patients (P=0.022, 0.043, 0.011). The incidence rates of lung cancer in patients in group B and C were 1.37 and 1.69 times higher than that in group A, respectively. Conclusion: The increased serum level of hs-CRP will increase the incidence rate of lung cancer in male patients with pulmonary tuberculosis.

Download Full-text

Clinical Evaluation of Hydroxyurea in Advanced Lung Cancer

Tumori Journal ◽

10.1177/030089166705300404 ◽

1967 ◽

Vol 53 (4) ◽

pp. 331-342 ◽

Cited By ~ 6

Author(s):

Gianni Bonadonna ◽

Silvio Monfardini ◽

Cesare Oldini ◽

Sergio Di Pietro

Keyword(s):

Lung Cancer ◽

Performance Status ◽

Objective Response ◽

Advanced Lung Cancer ◽

Total Daily Dose ◽

Bone Marrow Toxicity ◽

Cancer Group ◽

Group A ◽

Group B ◽

Epigastric Distress

Hydroxyurea has been adequately evaluated in 27 patients with inoperable or advanced lung cancer (group A). The drug was also given to 13 patients with miscellaneous metastatic solid tumors (group B). Four different dosages of hydroxyurea were administered: 40 mg/kg/day p.o. (15 patients of group A and 7 patients of group B); 10 mg/kg/day i.v. (3 patients of group A and 1 patient of group B); 100 mg/kg/week (3 patients of group A and 2 patients of group B); 100 mg/kg i.v. on alternate days (6 patients of group A and 3 patients of group B). The total daily dose was given in two administrations with an interval of 12 hours. None of the patients had been previously treated with radiotherapy or chemotherapy; their performance status was not less than 40. Subjective and objective responses, evaluated on the Karnofsky's categories, were seen in patients with advanced lung cancer, but only one patient of the miscellaneous group showed an objective response to hydroxyurea. The therapeutic responses were achieved in group A with dosages of 40 mg/kg/day p.o. (5/15 cases) and of 100 mg/kg i.v. on alternate days (4/6 cases). Relief of symptoms and objective regressions were short-lived. No maintenance treatment in responsive cases was given. There was no definite change in the basic course of the disease. The other patients treated respectively with 10 mg/kg/day and with 100 mg/kg/week were very few and received a smaller total dose of hydroxyurea. Bone marrow toxicity occurred mainly with patients receiving higher doses of hydroxyurea (40 mg/kg by mouth and 100 mg/kg i.v. on alternate days respectively). In these patients progressive leukopenia and anemia developed in almost every case, often requiring multiple blood transfusions. Megaloblastosis was checked in 3 cases. Five patients after 2–3 weeks of treatment had nasal bleeding, which disappeared spontaneously after 3–6 days. Only 2 patients, while receiving hydroxyurea by mouth, complained of nausea and epigastric distress and the drug was discontinued temporarily. Two patients showed a mild hyperuricemia after the first week of treatment. The administration of intravenous hydroxyurea at the dose of 100 mg/kg on alternate days in lung cancer deserves a more extensive trial.

Download Full-text

Postoperative radiation for lung cancer metastatic to the brain.

Journal of Clinical Oncology ◽

10.1200/jco.1994.12.11.2340 ◽

1994 ◽

Vol 12 (11) ◽

pp. 2340-2344 ◽

Cited By ~ 51

Author(s):

J G Armstrong ◽

M Wronski ◽

J Galicich ◽

E Arbit ◽

S A Leibel ◽

...

Keyword(s):

Lung Cancer ◽

Brain Metastases ◽

Survival Rates ◽

Term Survival ◽

Lung Cancer Patients ◽

C 23 ◽

Group A ◽

Group B ◽

The Impact ◽

The Brain

PURPOSE Although resection of single brain metastases and postoperative whole-brain radiation therapy (WBRT) improves survival, compared with treatment using WBRT alone, the value of postoperative WBRT after resection of brain metastases is controversial. We analyzed the largest reported series of lung cancer patients with resected brain metastases to evaluate the impact of postoperative WBRT. MATERIALS AND METHODS Between 1974 and 1989, 185 patients with non-small-cell lung cancer (NSCLC) underwent resection of brain metastases. Patients who had received preoperative WBRT (23%, 42 of 185) were excluded. The remaining patients were divided into group A (no WBRT; n = 32), group B (patients received WBRT and were prognostically matched to group A; n = 32), and group C (all other WBRT patients; n = 79). Most patients received postoperative doses of 30 Gy in 10 fractions. Higher doses were used in 16% of group B and 18% of group C patients. RESULTS Overall 5-year survival rates were as follows: group A, 12%; B, 8%; C, 16%. Overall brain failures occurred in 38% of patients in group A, 47% in group B, and 42% in group C. The use of WBRT (group A v groups B plus C) had no apparent impact on survival or on overall brain failure rates. In particular, no improvement in either of these parameters could be demonstrated when group B was compared with group A. Focal failure (defined as failure within the brain adjacent to the site of the resected brain metastases) occurred as follows: group A, 34% (11 of 32); groups B plus C, 23% (25 of 111) (P = .07). WBRT significantly reduced focal failure for patients with adenocarcinoma (group A, 33% [eight of 24]; groups B plus C, 14% [11 of 79]; P = .05). Nonfocal failure (anatomically distinct from the resected metastasis) occurred in 9% of patients in group A (three of 32), 21% in groups B plus C (23 of 111) (P = .07). CONCLUSION Long-term survival is possible when NSCLC brain metastases are resected. Postoperative WBRT as used in this series only had an impact on the focal control of brain metastases and this effect was of borderline significance. The lack of conclusive benefit supports the need for ongoing randomized trials to test the value of adjuvant postoperative WBRT. Brain failures were relatively common in all three groups of patients, which suggests that doses greater than 30 Gy need to be studied.

Download Full-text

Clinical Evaluation of Procarbazine and Fluorouracil in Advanced Lung Cancer

Tumori Journal ◽

10.1177/030089166905500504 ◽

1969 ◽

Vol 55 (5) ◽

pp. 277-290 ◽

Cited By ~ 6

Author(s):

Giovanni Bonadonna ◽

Silvio Monfardini ◽

Cesare Oldini ◽

Adalgiso Guzzon ◽

Sergio Di Pietro

Keyword(s):

Lung Cancer ◽

Side Effects ◽

Combined Treatment ◽

Advanced Lung Cancer ◽

Metastatic Lung ◽

Group A ◽

Group B ◽

Histologic Types ◽

Objective Improvement ◽

Better Than

Procarbazine and 5-fluorouracil were given to 69 untreated patients with inoperable or metastatic lung cancer. 62 were adequately evaluable. The patients were divided into 3 groups: A) 26 cases received procarbazine (250 mg/day i.v. for 4 weeks); B) 24 cases received procarbazine in association with 5-fluorouracil given by rapid single i.v. injection (10 mg/kg on alternate days for 4 weeks); C) 12 cases received procarbazine in association with 5-fluorouracil which was given by 2 hour i.v. infusion on alternate days for 4 weeks. No maintenance treatment was given. The objective responses were evaluated following the categories of Karnofsky. Considering only the category 1 responses, 15 % of patients of group A showed objective improvement, in comparison to 43 % and 16 % of patients of group B and C respectively. Therefore, it seems that the combination of procarbazine and 5-fluorouracil (rapid i.v. injection) is better than procarbazine alone, and that the combined treatment is more successful when 5-fluorouracil is given by single i.v. injection rather than through slow i.v. infusion. Regressions were observed in all histologic types. However, in the group of cases with adenocarcinoma none (0/5) responded to procarbazine alone but 5/6 to procarbazine plus 5-fluorouracil. It is likely that procarbazine is more effective in the oat-cell type and 5-fluorouracil in adenocarcinomas. Toxicity consisted in nausea and vomiting during the first 7–10 days in the group treated with procarbazine alone (15/26 cases), while only 2/26 patients had transient leukopenia. In group B the side-effects were diarrhea (13 cases) and leukopenia (9 cases), both possibly due to 5-fluorouracil. Only 2/12 patients of group C showed side-effects (1 vomiting and 1 diarrhea). The fact that no patients of this group showed signs of bone marrow depression confirms what is already known, i.e. that when 5-fluorouracil is given by slow i.v. infusion toxicity rarely occurs. The conclusion is that the association of procarbazine with 5-fluorouracil can produce consistent regressions in patients with advanced carcinoma of the lung, although unmaintained remissions are almost always short lived.

Download Full-text

Survival benefit of first-generation epidermal growth factor receptor–tyrosine kinase inhibitors in female with advanced lung cancer

Tumori Journal ◽

10.1177/0300891619839292 ◽

2019 ◽

Vol 105 (3) ◽

pp. 216-224

Author(s):

Byoung Soo Kwon ◽

Ji Hyun Park ◽

Seulgi Kim ◽

Sojung Park ◽

Wonjun Ji ◽

...

Keyword(s):

Lung Cancer ◽

First Generation ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Advanced Lung Cancer ◽

Group A ◽

Epidermal Growth ◽

Group B ◽

Egfr Tki ◽

Egfr Tkis

Background: This study aimed to estimate therapeutic effects of first-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) in real-world practice, by analyzing survival outcomes in an unselected, Korean female population with advanced lung cancer based on the National Health Insurance Service database. Methods: We identified women with newly diagnosed advanced lung cancer from January 2004 to December 2013. For progression-free survival (PFS) and overall survival (OS) analyses, patients were defined into the following subgroups: group A, treated with first-generation EGFR-TKI ⩾6 months; group B, treated with EGFR-TKIs <6 months but at least >1 month; and group C, treated with cytotoxic chemotherapy as follows: monotherapy or combination therapy with gemcitabine or pemetrexed; or monotherapy with docetaxel, paclitaxel, or vinorelbine. Results: Among 11,045 enrolled patients, 6170 (55.8%) were treated with first-generation EGFR-TKIs for at least 1 month. The median OS for patients treated with EGFR-TKIs was significantly longer than that of EGFR-TKI-naive patients (19.1 months [95% confidence interval (CI) 18.5–19.7] vs 9.5 months [95% CI 9.1–9.8], P<0.001). In subgroup analysis, group A had a significantly longer median OS compared with group B (30.3 months [95% CI 29.5–31.2] vs 12.3 months [95% CI 11.9–12.7], P<0.001). The median PFS of group A was significantly longer than that of group B (15.8 vs 3.7 months, P<0.001). Conclusions: Our analysis demonstrates that EGFR-TKIs confer significant PFS and OS benefits in the real-world practice for Korean female with advanced lung cancer.

Download Full-text

Relationship of subjective and objective sleep measures with physical performance in advanced-stage lung cancer patients

Scientific Reports ◽

10.1038/s41598-021-96481-7 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Naomi Takemura ◽

Denise Shuk Ting Cheung ◽

Daniel Yee Tak Fong ◽

Anne Wing Mui Lee ◽

Tai-Chung Lam ◽

...

Keyword(s):

Lung Cancer ◽

Sleep Quality ◽

Physical Function ◽

Cancer Patients ◽

Physical Performance ◽

Advanced Lung Cancer ◽

Stand Test ◽

Lung Cancer Patients ◽

Sit To Stand ◽

Multiple Covariates

AbstractAdvanced lung cancer patients suffer from deteriorated physical function, which negatively impacts physical and psychological health. As little is known about sleep and physical function in this population, this study aimed to examine the association between subjective and objective sleep parameters and physical function among them. 164 advanced lung cancer patients were included. Objective sleep was measured by actigraphy (measured on non-dominant wrist for 72 h), and subjective sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Performance-based physical function was measured by Timed Up and Go Test (TUGT), 6-Minute Walk Test (6MWT), Sit-to-Stand Test, and One-leg Standing Test. Univariable and multivariable regression analyses were employed to examine the association between sleep and physical function. Total sleep time (TST) was significantly associated with the 6MWT (β = 0.259; 95% CI 0.120, 0.398; P < 0.001), TUGT (β = − 0.012; 95% CI = − 0.017, − 0.008; P < 0.001) and Sit-to-Stand Test (β = 0.027; 95% CI = 0.018, 0.035; P < 0.001) after adjustment for multiple covariates. PSQI global score was only significantly associated with TUGT (β = 0.140; 95% CI = 0.000, 0.280; P = 0.050) after adjustment for multiple covariates. Shorter sleep duration significantly predicted poorer physical performance in advanced lung cancer patients, and more attention is required for those with less than 4.3 h of sleep on average.Trial registration: ClinicalTrials.gov, NCT03482323. Registered 29 March 2018, https://clinicaltrials.gov/ct2/show/NCT03482323; ClinicalTrials.gov, NCT04119778. Registered 8 October 2019, https://clinicaltrials.gov/ct2/show/NCT04119778.

Download Full-text